AAV5 possesses distinct genetic and structural features compared to AAV2, resulting in a unique mechanism of cellular uptake and lack of cross-complementation.
No takes yet. Share an insight, caveat, or question.
Requires serotype-specific vector evaluation in gene therapy; leaves open optimal AAV choice for clinical translation.
Chiorini et al. (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: